Cargando…
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
BACKGROUND: Genetic alterations in ARID1A were detected at a high frequency in cholangiocarcinoma (CCA). Growing evidence indicates that the loss of ARID1A expression leads to activation of the PI3K/AKT pathway and increasing sensitivity of ARID1A-deficient cells for treatment with the PI3K/AKT inhi...
Autores principales: | Tessiri, Supharada, Techasen, Anchalee, Kongpetch, Sarinya, Namjan, Achira, Loilome, Watcharin, Chan-on, Waraporn, Thanan, Raynoo, Jusakul, Apinya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761367/ https://www.ncbi.nlm.nih.gov/pubmed/35070505 http://dx.doi.org/10.7717/peerj.12750 |
Ejemplares similares
-
ARID1A alterations and their clinical significance in cholangiocarcinoma
por: Namjan, Achira, et al.
Publicado: (2020) -
Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma
por: Wintachai, Preawwalee, et al.
Publicado: (2021) -
Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms
por: Kimawaha, Phongsaran, et al.
Publicado: (2021) -
Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression
por: Armartmuntree, Napat, et al.
Publicado: (2021) -
Upregulation of TCTP is associated with cholangiocarcinoma progression and metastasis
por: Phanthaphol, Nattaporn, et al.
Publicado: (2017)